Velvio develops state-of-the-art antisense oligonucleotide drugs that exert their effect by decreasing synthesis of a single protein. In Velvio's development concept, these drugs are used to restore organ repair functions, initially for the treatment of rare "orphan" diseases in neurodegeneration and lung diseases; the first target indications are ALS and IPF, both diseases are always life-threatening and so far, not treatable for their cause. There are few approved treatment options available with limited efficacy. In addition, Velvio's antisense candidate library offers opportunities in immune oncology and new treatment concepts for brain and liver tumors. Here too, initial R&D results are quite promising.
|Velvio’s NVP-Products||R&D||Preclinical||Phase Ib / IIa||Phase IIb / III||MAA3|
|IP-Protected NVP Portfolio (>200 candidates)|
|NVP-13: ALS / Neurodegeneration||*||2024|
|NVP-13/-19: Lung IPF1/BPD2 (pediatric)||*||*||2024|
|NVP-X: Liver Diseases||*||2025|